MEDICINOVA INC (MNOV) Stock Fundamental Analysis
NASDAQ:MNOV - Nasdaq - US58468P2065 - Common Stock - Currency: USD
We assign a fundamental rating of 3 out of 10 to MNOV. MNOV was compared to 558 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MNOV as it has an excellent financial health rating, but there are worries on the profitability. MNOV is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
MNOV had negative earnings in the past year.
In the past year MNOV has reported a negative cash flow from operations.
In the past 5 years MNOV always reported negative net income.
MNOV had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
MNOV has a better Return On Assets (-19.78%) than 78.14% of its industry peers.
Looking at the Return On Equity, with a value of -21.05%, MNOV belongs to the top of the industry, outperforming 84.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.78% | ||
| ROE | -21.05% | ||
| ROIC | N/A |
ROA(3y)-17.22%
ROA(5y)-16.33%
ROE(3y)-18.28%
ROE(5y)-17.27%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for MNOV so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MNOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
MNOV has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for MNOV has been increased compared to 5 years ago.
There is no outstanding debt for MNOV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
MNOV has an Altman-Z score of 0.46. This is a bad value and indicates that MNOV is not financially healthy and even has some risk of bankruptcy.
MNOV has a Altman-Z score of 0.46. This is in the better half of the industry: MNOV outperforms 64.16% of its industry peers.
MNOV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.46 |
ROIC/WACCN/A
WACC9.68%
2.3 Liquidity
A Current Ratio of 13.88 indicates that MNOV has no problem at all paying its short term obligations.
With an excellent Current ratio value of 13.88, MNOV belongs to the best of the industry, outperforming 85.48% of the companies in the same industry.
A Quick Ratio of 13.88 indicates that MNOV has no problem at all paying its short term obligations.
The Quick ratio of MNOV (13.88) is better than 85.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.88 | ||
| Quick Ratio | 13.88 |
3. Growth
3.1 Past
The earnings per share for MNOV have decreased strongly by -35.29% in the last year.
The Revenue for MNOV has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-35.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 11.64% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-77.39%
EPS Next 2Y-25.47%
EPS Next 3Y-21.05%
EPS Next 5Y11.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MNOV. In the last year negative earnings were reported.
Also next year MNOV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MNOV's earnings are expected to decrease with -21.05% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.47%
EPS Next 3Y-21.05%
5. Dividend
5.1 Amount
No dividends for MNOV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.2698
0 (-0.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners21.9%
Inst Owner Change0%
Ins Owners2.98%
Ins Owner Change0%
Market Cap62.28M
Analysts82.5
Price Target7.14 (462.29%)
Short Float %0.34%
Short Ratio13.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.5%
Min EPS beat(2)-6.95%
Max EPS beat(2)1.96%
EPS beat(4)2
Avg EPS beat(4)-1.08%
Min EPS beat(4)-17.65%
Max EPS beat(4)18.3%
EPS beat(8)6
Avg EPS beat(8)19.04%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.67%
PT rev (3m)-16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)20%
EPS NY rev (3m)-8.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.19 | ||
| P/tB | 1.63 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS1.07
TBVpS0.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.78% | ||
| ROE | -21.05% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-17.22%
ROA(5y)-16.33%
ROE(3y)-18.28%
ROE(5y)-17.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.27% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 13.88 | ||
| Quick Ratio | 13.88 | ||
| Altman-Z | 0.46 |
F-Score2
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)53.06%
Cap/Depr(5y)91.84%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-77.39%
EPS Next 2Y-25.47%
EPS Next 3Y-21.05%
EPS Next 5Y11.64%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.22%
OCF growth 3YN/A
OCF growth 5YN/A